Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 653 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Adult Participants Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

NCT07249463
View directory record Official record
Conditions
Cryptosporidiosis
Interventions
Cryptosporidium parvum oocysts (ABO809), EDI048, Placebo
Biological · Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

NCT04410094
View directory record Official record
Conditions
Healthy
Interventions
Lazertinib, Itraconazole, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

NCT03627494
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
GSK3439171A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

NCT06722430
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icalcaprant, Itraconazole (ITZ)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MK-0616
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 9, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kimchi and Gut Health

NCT07435831
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
60 grams per day of intervention food
Other
Lead sponsor
University of California, Davis
Other
Eligibility
19 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial Investigating Lu AF28996 in Healthy Adult Participants

NCT06277609
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AF28996, Acetylsalicylic Acid, Mefenamic Acid, Amoxicillin/clavulanic acid
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Microtracer [14C]ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

NCT04194892
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Pegilodecakin
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

NCT05134350
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LOXO-305, Omeprazole
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 9, 2026, 8:23 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

NCT07801456
View directory record Official record
Conditions
Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
Interventions
VIR-1388, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Acute Effects of Alpha-glycerylphosphorylcholine (A-GPC) on Lower Body Muscular Performance.

NCT07397273
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
L-Alpha glycerylphosphorylcholine, Microcrystalline Cellulose
Dietary Supplement
Lead sponsor
Northern Illinois University
Other
Eligibility
19 Years to 29 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Osteopathic Manipulation on Circulating Immune Markers

NCT07622966
View directory record Official record
Conditions
Healthy Adult Participants, Osteopathic Manipulative Treatment (OMT)
Interventions
Osteopathic Manipulative Treatment (OMT), Sham Comparator
Other
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Monroe, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

NCT07216131
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD0780, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants

NCT07050511
View directory record Official record
Conditions
SARS CoV-2
Interventions
GB-0669, Placebo
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

NCT03267732
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Pegilodecakin
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

NCT03735849
View directory record Official record
Conditions
HIV Infections
Interventions
VRC07-523LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants

NCT05767398
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

NCT04628793
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07258669, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 9, 2026, 8:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

NCT05475821
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-990, Placebo for ABBV-990
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

NCT06058390
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 9, 2026, 8:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

NCT05630274
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Moxifloxacin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 9, 2026, 8:23 AM EDT